Neogen (NEOG) Q1 2027 earnings review
Neogen grew sales quickly, but its full-year plan expects stagnation
Neogen's core food and animal safety businesses are growing again as the company clears its recent execution problems. Sales grew 6%, and profit margins expanded because the company spent less money integrating past acquisitions. Chief executive Mike Nassif raised the full-year outlook, but by our math the plan has sales growth stopping completely in the final three quarters.
| Sales from businesses owned a year ago | 8% 4.3% last quarter |
|---|---|
| Profit before one-offs and tax | $41.6 million plan pointed to $37 million |
| Full-year sales outlook | Raised $5 million middle of the range: 2% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because Neogen cleared its biggest near-term execution risk. The company fully validated its first in-house test product on schedule, which keeps its profit recovery plan on track. The bad news: management raised the full-year outlook by less than the size of the first-quarter beat. The conservative plan suggests the sales team has not fully recovered yet.
The question now is whether the first quarter's pace can hold. A strong second quarter means the turnaround is real, while flat sales mean the first quarter only pulled customer orders forward. Next quarter's underlying sales growth will tell.
🐂 Bull Case
Underlying Sales Accelerated
Neogen measures underlying sales by excluding currency moves and businesses it sold. Underlying sales grew 8% this quarter. The company said the "timing of certain customer orders" added about 3 percentage points.
By our math, the clean growth rate was still 5%. This beats the company's own full-year plan of 3% growth. The strong quarter shows the company is winning back customers after last year's supply problems.
What to watch: whether underlying sales stay above 5% next quarter. Two strong quarters in a row would prove the recovery is real.
Factory Transition On Track
Neogen relies on an external partner to manufacture Petrifilm, its food testing product. The company plans to bring production into its own factory to improve profit margins. A delay would keep manufacturing costs high.
The company successfully validated the first product on schedule in August. Neogen said it remains on track to begin producing sellable product in November. This clears the largest execution risk the company faced this year.
What to watch: the number of products transferred by the end of next quarter. The company must move 17 different products to fully exit the external contract.
Profit Margins Expanded
Profitability improved as the company moved past the heavy costs of combining businesses. Gross margin rose 2 percentage points from a year ago. Neogen said it spent less on integrating the former 3M food safety business.
The higher margin turned a 6% increase in sales into a 17% jump in operating profit. By our math, the profit beat the company's own guidance.
What to watch: whether gross margin stays above 47% as the factory transition continues. High costs during the move could squeeze the margin again.
🐻 Bear Case
The Plan Expects Stagnation
Chief executive Mike Nassif said the company's focus shifted to scaling its fundamentals. But the company's own outlook does not expect the current growth to last.
Neogen raised its full-year sales outlook by $5 million. The company beat its first-quarter sales target by $15 million. By our math, the new plan leaves only about 0.5% growth for the rest of the year.
What to watch: whether the company raises the plan next quarter. A flat plan means management believes the first quarter only pulled future orders forward.
Risks this quarter didn't answer
Two standing concerns got no new numbers in the press release. Each one has a disclosure that would settle it.
- Sample collection margin: missing for a fifth quarter; any disclosed figure would show how much money the product line loses.
- Restructuring savings: missing for a fourth quarter; the filing's expense tables will show the exact impact on overhead.
💲 Other KPIs
Falling slowly as the company pays down its loans. Debt dropped 2.5% from last quarter. Neogen plans to use cash from its upcoming Genomics business sale to speed up debt reduction.
Increased slightly from last quarter after falling steadily for most of last year. Inventory is the stock of raw materials and finished goods the company holds. A rising stock ties up cash that could otherwise pay down debt.
🔮 Guidance
Raised. The middle of the range moved up $5 million, to about 2% growth. The new plan absorbs the strong first quarter but expects almost no growth for the rest of the year.
Raised. The middle of the range moved up $1 million. The company expects profit to grow slower than sales for the full year as it spends more money on research and new computer systems.
❓ Key Questions
Sample collection margin
What is the sample collection product line's current gross margin? The figure bounds the turnaround's profit case but remains undisclosed.
Implied stagnation
If underlying sales grew 5% cleanly in the first quarter, why does the guidance imply less than 1% growth for the rest of the year?
Petrifilm validation cadence
What is the specific timeline for validating the remaining 16 Petrifilm products, and what happens if the external supply agreement expires first?